Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and management of dementia: a review. JAMA. 2019;322:1589–99. https://doi.org/10.1001/jama.2019.4782.

Article  PubMed  PubMed Central  Google Scholar 

GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7:e105–25. https://doi.org/10.1016/S2468-2667(21)00249-8.

Article  Google Scholar 

Nandi A, Counts N, Chen S, Seligman B, Tortorice D, Vigo D, et al. Global and regional projections of the economic burden of Alzheimer's disease and related dementias from 2019 to 2050: a value of statistical life approach. EClinicalMedicine, 2022;51:101580. https://doi.org/10.1016/j.eclinm.2022.101580.

Steinberg M, Shao H, Zandi P, Lyketsos CG, Welsh-Bohmer KA, Norton MC, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2008;23:170–7. https://doi.org/10.1002/gps.1858.

Article  PubMed  PubMed Central  Google Scholar 

Karttunen K, Karppi P, Hiltunen A, Vanhanen M, Välimäki T, Martikainen J, et al. Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer’s disease. Int J Geriatr Psychiatry. 2011;26:473–82. https://doi.org/10.1002/gps.2550.

Article  PubMed  Google Scholar 

Huang M-F, Lee W-J, Yeh Y-C, Lin Y-S, Lin H-F, Wang S-J, et al. Neuropsychiatric symptoms and mortality among patients with mild cognitive impairment and dementia due to Alzheimer’s disease. J Formos Med Assoc. 2022;121:1705–13. https://doi.org/10.1016/j.jfma.2021.12.004.

Article  PubMed  Google Scholar 

Majer R, Adeyi O, Bagoly Z, Simon V, Csiba L, Kardos L, et al. Neuropsychiatric symptoms, quality of life and caregivers’ burden in dementia. Open Med. 2020;15:905–14. https://doi.org/10.1515/med-2020-0124.

Article  Google Scholar 

Huang Y-J, Lin C-H, Lane H-Y, Tsaid GE. NMDA neurotransmission dysfunction in behavioral and psychological symptoms of Alzheimer’s disease. Curr Neuropharmacol. 2012;10:272–85. https://doi.org/10.2174/157015912803217288.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang HJ, Chinna-Meyyappan A, Feldman OJ, Lanctôt KL. Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer’s disease. Expert Opin Emerg Drugs. 2024;29:289–303. https://doi.org/10.1080/14728214.2024.2363215.

Article  CAS  PubMed  Google Scholar 

Yunusa I, El Helou ML. The use of risperidone in behavioral and psychological symptoms of dementia: a review of pharmacology, clinical evidence, regulatory approvals, and off-label use. Front Pharmacol. 2020;11:596. https://doi.org/10.3389/fphar.2020.00596.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nakamura Y, Adachi J, Hirota N, Iba K, Shimizu K, Nakai M, et al. Brexpiprazole treatment for agitation in Alzheimer’s dementia: a randomized study. Alzheimers Dement. 2024;20:8002–11. https://doi.org/10.1002/alz.14282.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Washington T. New research supports Nuplazid® (pimavanserin) use in Parkinson’s disease dementia. Lewy Body Dementia Association. 2024. https://www.lbda.org/new-research-supports-nuplazid-pimavanserin-use-in-parkinsons-disease-dementia/. Accessed 17 Oct 2025.

Weintraub D, Espay AJ, Sharma VD, Tariot PN, Abler V, Pathak S, et al. Pimavanserin for psychosis in Parkinson’s disease dementia: subgroup analysis of the HARMONY trial. Parkinsonism Relat Disord. 2024;119:105951. https://doi.org/10.1016/j.parkreldis.2023.105951.

Article  CAS  PubMed  Google Scholar 

Acadia Pharmaceuticals Inc. Acadia Pharmaceuticals receives complete response letter from U.S. FDA for supplemental new drug application for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis. Available from: https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-receives-complete-response-letter-us-0. Accessed 17 Oct 2025.

Alzheimer's Association. FDA rejects application of pimavanserin for the treatment of hallucinations and delusions due to dementia-related psychosis. 2021. https://www.alz.org/news/2021/fda-rejects-application-of-pimavanserin-for-the-treatment-of-hallucinations-and-delusions-due-to-de. Accessed 6 Oct 2025.

Kheirbek RE, Fokar A, Little JT, Balish M, Shara NM, Boustani MA, et al. Association between antipsychotics and all-cause mortality among community-dwelling older adults. J Gerontol A Biol Sci Med Sci. 2019;74:1916–21. https://doi.org/10.1093/gerona/glz045.

Article  PubMed  PubMed Central  Google Scholar 

Mok PLH, Carr MJ, Guthrie B, Morales DR, Sheikh A, Elliott RA, et al. Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study. BMJ. 2024;385:e076268. https://doi.org/10.1136/bmj-2023-076268.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stella F, Valiengo LCL, de Paula VJR, Lima CAdeM, Forlenza OV. Medical cannabinoids for treatment of neuropsychiatric symptoms in dementia: a systematic review. Trends Psychiatry Psychother. 2021;43:243–55. https://doi.org/10.47626/2237-6089-2021-0288.

Article  PubMed  PubMed Central  Google Scholar 

Liu CS, Chau SA, Ruthirakuhan M, Lanctôt KL, Herrmann N. Cannabinoids for the treatment of agitation and aggression in Alzheimer’s disease. CNS Drugs. 2015;29:615–23. https://doi.org/10.1007/s40263-015-0270-y.

Article  CAS  PubMed  Google Scholar 

Sherman C, Ruthirakuhan M, Vieira D, Lanctôt KL, Herrmann N. Cannabinoids for the treatment of neuropsychiatric symptoms, pain and weight loss in dementia. Curr Opin Psychiatry. 2018;31:140–6. https://doi.org/10.1097/YCO.0000000000000399.

Article  PubMed  Google Scholar 

Velayudhan L, McGoohan K, Bhattacharyya S. Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: a systematic review and meta-analysis. PLoS Med. 2021;18:e1003524. https://doi.org/10.1371/journal.pmed.1003524.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cuttler C, Spradlin A, McLaughlin RJ. A naturalistic examination of the perceived effects of cannabis on negative affect. J Affect Disord. 2018;235:198–205. https://doi.org/10.1016/j.jad.2018.04.054.

Article  PubMed  Google Scholar 

Cuttler C, Stueber A, Cooper ZD, Russo E. Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial. Sci Rep. 2024;14:16163. https://doi.org/10.1038/s41598-024-66879-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tadijan A, Vlašić I, Vlainić J, Đikić D, Oršolić N, Jazvinšćak Jembrek M. Intracellular molecular targets and signaling pathways involved in antioxidative and neuroprotective effects of cannabinoids in neurodegenerative conditions. Antioxidants. 2022;11:2049. https://doi.org/10.3390/antiox11102049.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Donvito G, Nass SR, Wilkerson JL, Curry ZA, Schurman LD, Kinsey SG, et al. The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain. Neuropsychopharmacology. 2018;43:52–79. https://doi.org/10.1038/npp.2017.204.

Article  CAS  PubMed  Google Scholar 

Tyrakis P, Agridi C, Kourti M. A comprehensive exploration of the multifaceted neuroprotective role of cannabinoids in Alzheimer’s disease across a decade of research. Int J Mol Sci. 2024;25:8630. https://doi.org/10.3390/ijms25168630.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cummings JL, Brubaker M, Selzler KJ, Gonzalez ST, Patel M, Stahl SM. An overview of the pathophysiology of agitation in Alzheimer’s dementia with a focus on neurotransmitters and circuits. CNS Spectr. 2024;29:316–25. https://doi.org/10.1017/S1092852924000427.

Article  Google Scholar 

Bietar B, Tanner S, Lehmann C. Neuroprotection and beyond: the central role of CB1 and CB2 receptors in stroke recovery. Int J Mol Sci. 2023;24:16728. https://doi.org/10.3390/ijms242316728.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang W, Xiao D, Mao Q, Xia H. Role of neuroinflammation in neurodegeneration development. Signal Transduct Target Ther. 2023;8:267. https://doi.org/10.1038/s41392-023-01486-5.

Article  PubMed  PubMed Central  Google Scholar 

García-Gutiérrez MS, Torregrosa AB, Navarrete F, Navarro D, Manzanares J. A comprehensive review of the multifaceted role of cannabinoid receptor type 2 in neurodegenerative and neuropsychiatric disorders. Pharmacol Res. 2025;213:107657. https://doi.org/10.1016/j.phrs.2025.107657.

Article  CAS  PubMed